A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

Study Overview
=================
Brief Summary
-----------------
The purposes of this study are: To see how the new medicine (PF-07853578) under study is tolerated. And if there are any important side effects. And, how people feel after taking single increasing amount of the medicine by mouth. To measure the amount of study medicine in your blood after the medicine is taken by mouth. This study is seeking for participants who: are females of 18 to 65 years old and are not able to give birth to a child. are males of 18 to 65 years old. have body mass index of 16 to 31 kilograms per meter squared. have a total body weight of more than 50 kilograms (110 pounds). Participants will be randomly selected to receive either study medicine (PF-07853578) or placebo (a pill that has no medicine in it). Participants may receive up to 4 amounts of study medicine and up to 2 amounts of placebo.

Official Title
-----------------
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Crossover, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of PF-07853578 Administered to Healthy Adult Participants

Conditions
-----------------
Healthy Participants

Intervention / Treatment
-----------------
* Drug: PF-07853578
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female participants of non-childbearing potential and male participants aged 18 to 65 years at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. BMI of 16 to 30.5 kg/m2; and a total body weight >50 kg (110 lb). Exclusion Criteria: Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention, with the exception of moderate or strong cytochrome P450 3A (CYP3A) inducers or inhibitors which are prohibited within 14 days plus 5 half-lives prior to the first dose of study intervention. Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study. Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) for participants <60 years; and ≥150/90 mm/Hg for participants ≥60 years old, following at least 5 minutes of supine rest. Renal impairment as defined by an estimated glomerular filtration rate (eGFR) of <75 mL/min/1.73m². Hematuria as defined by >1+ heme on urine dipstick. Albuminuria as defined by albumin/creatine (Cr) ratio on spot urine albumin (UA) >30 mg/g. Standard 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), Bilirubin ≥1.05×ULN. Total cholesterol, triglycerides, or direct LDL ≥1.25×ULN.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1<br>Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo. | Drug: PF-07853578<br>* PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.<br>Drug: Placebo<br>* Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.<br>|
| Experimental: Cohort 2<br>Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo. | Drug: PF-07853578<br>* PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.<br>Drug: Placebo<br>* Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.<br>|
| Experimental: Cohort 3<br>Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo. | Drug: PF-07853578<br>* PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.<br>Drug: Placebo<br>* Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) Following Single Ascending Dose |  | Day 1 to Day 10 in each period | 
| Number of Participants With Clinical Laboratory Abnormalities |  | Day 1 to Day 10 in each period | 
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs |  | Day 1 to Day 10 in each period | 
| Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings |  | Day 1 to Day 10 in each period | 
| Number of Participants With Clinically-Significant Change From Baseline in Neurological Examination Findings |  | Day 1 to Day 10 in each period | 
| Number of Participants With Clinically Significant Change From Baseline in Telemetry Findings |  | 0 to 8 hours post-dose on Day 1 in each period | 
| Number of Participants With Clinically-Significant Change From Baseline in Physical Examination Findings |  | Day 1 to Day 10 in each period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Observed Plasma Concentration (Cmax) of PF-07853578 |  | Day 1 0 hour to 72 hours post-dose in each period | 
| Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of PF-07853578 |  | Day 1 0 hour to 72 hours post-dose in each period | 
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07853578 |  | Day 1 0 hour to 72 hours post-dose in each period | 
| Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07853578 |  | Day 1 0 hour to 72 hours post-dose in each period | 
| Plasma Half-Life (t1/2) of PF-07853578 |  | Day 1 0 hour to 72 hours post-dose in each period |